NICE (UK) 1.1 Elranatamab is recommended with managed access as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of… read more.
GSK plc announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with… read more.
Roche announced data from a 5-year follow-up of the pivotal phase III POLARIX study. Data were presented in an oral session at the 66th American Society of Hematology… read more.
Researchers report that a diet low in omega-6 and high in omega-3 fatty acids, combined with fish oil supplements has led to a reduced growth rate of prostate… read more.
Novartis announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 96 . The study… read more.
Researchers report that, among patients with high-risk smoldering multiple myeloma, treatment with daratumumab appears to be associated with a significantly lower risk of progression to active multiple myeloma… read more.
Roche announced the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of people… read more.
Novartis announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive,… read more.
AbbVie announced the European Commission (EC) granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous… read more.
Hair loss during chemotherapy can cause enough distress for some women to lose self-confidence, which experts say may discourage them from seeking chemotherapy in the first place. Oral… read more.
Lung cancer screening with low-dose chest computed tomography (CT) has the potential to detect coronary artery calcium too, researchers reported on Dec. 2, 2024 in the CMAJ (Canadian Medical Association… read more.
Lung cancer screening with low-dose chest computed tomography (CT) may detect more than just lung cancer. As new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.231602 shows, these CTs can identify coronary… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
